Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors

Traditional Histone deacetylase 8 (HDAC8) inhibitors primarily rely on hydroxamate-based scaffolds. However, there is a growing interest in developing non-hydroxamate inhibitors to overcome potential limitations with hydroxamate-based inhibitors. In this study, we report the design, synthesis, and e...

Full description

Saved in:
Bibliographic Details
Main Authors: N.V.M. Rao Bandaru, Ashna Fathima, Vandana Joshi, Markus Schweipert, Obanna Pathur, Kosana Sai Chaitanya, Trinath Jamma, Vivek Sharma, Chandrasekhar Abbineni, Franz-Josef Meyer-Almes, Kondapalli Venkata Gowri Chandra Sekhar
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:European Journal of Medicinal Chemistry Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772417425000111
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849773146869071872
author N.V.M. Rao Bandaru
Ashna Fathima
Vandana Joshi
Markus Schweipert
Obanna Pathur
Kosana Sai Chaitanya
Trinath Jamma
Vivek Sharma
Chandrasekhar Abbineni
Franz-Josef Meyer-Almes
Kondapalli Venkata Gowri Chandra Sekhar
author_facet N.V.M. Rao Bandaru
Ashna Fathima
Vandana Joshi
Markus Schweipert
Obanna Pathur
Kosana Sai Chaitanya
Trinath Jamma
Vivek Sharma
Chandrasekhar Abbineni
Franz-Josef Meyer-Almes
Kondapalli Venkata Gowri Chandra Sekhar
author_sort N.V.M. Rao Bandaru
collection DOAJ
description Traditional Histone deacetylase 8 (HDAC8) inhibitors primarily rely on hydroxamate-based scaffolds. However, there is a growing interest in developing non-hydroxamate inhibitors to overcome potential limitations with hydroxamate-based inhibitors. In this study, we report the design, synthesis, and evaluation of a series of benzyl-1,2,4-triazolo [4,3-a] pyridine derivatives as non-hydroxamate HDAC8 inhibitors. Their HDAC8 inhibitory activities were assessed by enzymatic assay. Active compounds from the HDAC8 enzymatic assay were evaluated in various cancer cell lines, revealing that compound 9i demonstrated significant anti-neuroblastoma activity. Docking studies on compound 9i were conducted to explicate its structural basis. The additional experiments showed that compound 9i inhibited colony formation, induced hyperacetylation of SMC3, suppressed cell migration, triggered apoptosis, and caused cell cycle arrest in IMR-32 neuroblastoma cells. Overall, these inhibitors showed promising activity and a strong correlation with observed phenotypic effects, suggesting their potential for further development as therapeutic agents for cancer treatment.
format Article
id doaj-art-bd96f889b51e4a4eb69d63c68a46af28
institution DOAJ
issn 2772-4174
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series European Journal of Medicinal Chemistry Reports
spelling doaj-art-bd96f889b51e4a4eb69d63c68a46af282025-08-20T03:02:07ZengElsevierEuropean Journal of Medicinal Chemistry Reports2772-41742025-04-011310025510.1016/j.ejmcr.2025.100255Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitorsN.V.M. Rao Bandaru0Ashna Fathima1Vandana Joshi2Markus Schweipert3Obanna Pathur4Kosana Sai Chaitanya5Trinath Jamma6Vivek Sharma7Chandrasekhar Abbineni8Franz-Josef Meyer-Almes9Kondapalli Venkata Gowri Chandra Sekhar10Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, India; Aurigene Oncology Limited, 39-40 KIADB Industrial Area Electronic City Phase II, Hosur Road, Bangalore 560 100, IndiaDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, IndiaDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, IndiaDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany; European University of Technology, Darmstadt, GermanyAurigene Oncology Limited, 39-40 KIADB Industrial Area Electronic City Phase II, Hosur Road, Bangalore 560 100, IndiaDepartment of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, IndiaDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, IndiaDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, IndiaAurigene Oncology Limited, 39-40 KIADB Industrial Area Electronic City Phase II, Hosur Road, Bangalore 560 100, IndiaDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany; European University of Technology, Darmstadt, Germany; Corresponding author. Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, India; Corresponding author. Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.Traditional Histone deacetylase 8 (HDAC8) inhibitors primarily rely on hydroxamate-based scaffolds. However, there is a growing interest in developing non-hydroxamate inhibitors to overcome potential limitations with hydroxamate-based inhibitors. In this study, we report the design, synthesis, and evaluation of a series of benzyl-1,2,4-triazolo [4,3-a] pyridine derivatives as non-hydroxamate HDAC8 inhibitors. Their HDAC8 inhibitory activities were assessed by enzymatic assay. Active compounds from the HDAC8 enzymatic assay were evaluated in various cancer cell lines, revealing that compound 9i demonstrated significant anti-neuroblastoma activity. Docking studies on compound 9i were conducted to explicate its structural basis. The additional experiments showed that compound 9i inhibited colony formation, induced hyperacetylation of SMC3, suppressed cell migration, triggered apoptosis, and caused cell cycle arrest in IMR-32 neuroblastoma cells. Overall, these inhibitors showed promising activity and a strong correlation with observed phenotypic effects, suggesting their potential for further development as therapeutic agents for cancer treatment.http://www.sciencedirect.com/science/article/pii/S2772417425000111Histone deacetylaseBenzyl-1,2,4-triazolo[4,3-a] pyridineInhibitorsAnti-proliferativeDocking
spellingShingle N.V.M. Rao Bandaru
Ashna Fathima
Vandana Joshi
Markus Schweipert
Obanna Pathur
Kosana Sai Chaitanya
Trinath Jamma
Vivek Sharma
Chandrasekhar Abbineni
Franz-Josef Meyer-Almes
Kondapalli Venkata Gowri Chandra Sekhar
Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
European Journal of Medicinal Chemistry Reports
Histone deacetylase
Benzyl-1,2,4-triazolo[4,3-a] pyridine
Inhibitors
Anti-proliferative
Docking
title Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
title_full Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
title_fullStr Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
title_full_unstemmed Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
title_short Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
title_sort design synthesis and biological evaluation of substituted benzyl triazolopyridine derivatives as non hydroxamate based hdac8 inhibitors
topic Histone deacetylase
Benzyl-1,2,4-triazolo[4,3-a] pyridine
Inhibitors
Anti-proliferative
Docking
url http://www.sciencedirect.com/science/article/pii/S2772417425000111
work_keys_str_mv AT nvmraobandaru designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT ashnafathima designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT vandanajoshi designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT markusschweipert designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT obannapathur designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT kosanasaichaitanya designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT trinathjamma designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT viveksharma designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT chandrasekharabbineni designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT franzjosefmeyeralmes designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors
AT kondapallivenkatagowrichandrasekhar designsynthesisandbiologicalevaluationofsubstitutedbenzyltriazolopyridinederivativesasnonhydroxamatebasedhdac8inhibitors